Skip to main navigationSkip to main content
The University of Southampton
OLIGOMED - Oligonucleotides for medical applications

Dr. Anna Perdrix Rosell

Anna Perdrix Rosell

Anna Perdix Rosell is Managing Director and leads Sixfold Bioscience’s R&D team.


Anna Perdrix Rosell is currently the Managing Director at Sixfold Bioscience, where she leads a multidisciplinary team of scientists at the interface of biology, chemistry and computation. After graduating from University of Barcelona with a BSc in Biomedical Sciences, Anna went on to complete her MRes in Translational Cancer Medicine at King’s College London and PhD in Cancer Research at the Francis Crick Institute, London. She complemented her scientific training with an MBA.

During her doctoral studies she became deeply interested in science translation and co-founded Sixfold Bioscience together with a PhD graduate from the University of Cambridge. Sixfold is a venture-backed start-up at the forefront of developing an oligonucleotide-based therapeutic delivery platform for RNA Therapeutics.

Her scientific contributions have been published in prestigious journals (e.g. Current Biology, Cell and Nature Medicine) and have led to multiple patent applications. Dr. Perdrix Rosell is lead investigator in 10+ grants awarded by H2020 and UK funding bodies, including leading multi-million pan-european consortiums, and is a current Royal Academy of Engineering SME Leader, and member of the Advisory Board of the EPSRC funded Portabolomics consortium. Her scientific entrepreneurial journey has been recognised by Forbes on the 30 under 30 Science and Healthcare list (2018)), by Cancer Research UK and The Francis Crick Institute as a Future Science Leader (2018), by The Guardian as a Rising Star of Science (2019) and by The Maserati & The Sunday Times Top 100 British Entrepreneurs (2019).


Website (Sixfold Bioscience)

Privacy Settings